PYRILUTAMIDE 0.5%
PYRILUTAMIDE 0.5%
Single-compound, solvent-based topical research formulation developed for localized, non-clinical androgen receptor interaction studies.
Prefer email communication?
Request this formulation via our consultation form.
Request-only supply. No instant checkout. All formulation requests are reviewed before fulfilment.
Technical Data
Chemical Identification
KX-826
Physicochemical Characteristics
Documentation & Analytical Data
Research Documentation
Formulation Specification
Concentration system: 0.5% w/v
Equivalent concentration: 5 mg/mL
Total active content: 250 mg per 50 mL
Vehicle system: Ethanol 96% (Ph. Eur.) / Propylene Glycol (Ph. Eur.) / Diethylene Glycol Monoethyl Ether — Transcutol® P (Ph. Eur.) / Dimethyl Isosorbide
Solvent ratio: 40 / 12.5 / 37.5 / 10
Formulation architecture: Multi-solvent topical carrier system designed to support compound solubility, formulation consistency, and controlled surface application modeling.
Water content: No added water
Formulation complexity: Single-compound system
Research Context
Pyrilutamide is a non-steroidal androgen receptor antagonist investigated in non-clinical research models involving localized androgen receptor interaction.
In topical research contexts, Pyrilutamide formulations are commonly evaluated as surface-applied compounds where localized delivery behavior, receptor-associated activity, and carrier-system compatibility are relevant experimental parameters.
Experimental focus is generally directed toward localized androgen receptor interaction models, formulation dispersion behavior, and controlled surface-level delivery architecture within non-clinical laboratory environments.
This GeneTherica formulation is positioned as a research-grade topical solution for controlled, non-clinical laboratory use. It is not supplied for therapeutic, diagnostic, cosmetic, or human application.
Storage & Handling
Storage range: 2–8°C preferred; 15–25°C acceptable for short-term controlled handling.
Storage conditions: Store tightly closed in a cool, dry, dark environment.
Light sensitivity: Protect from direct sunlight and UV exposure.
Temperature stability: Avoid freezing and excessive heat exposure.
Air exposure: Minimize prolonged exposure to air.
Closure requirement: Keep container tightly sealed when not in use.
Stability context: Storage conditions are intended to support solvent balance, formulation consistency, and compound integrity during controlled non-clinical handling.
Research Use Notice
Supplied exclusively for laboratory research and analytical applications.
Not intended for therapeutic, cosmetic, veterinary, food, household, diagnostic, or human application.
Handling should occur within qualified non-clinical research environments only.
Overview
Pyrilutamide is a non-steroidal androgen receptor antagonist investigated within controlled research environments involving localized androgen receptor interaction and tissue-level signaling models.
Within topical research frameworks, Pyrilutamide formulations are primarily examined for their localized interaction with androgen receptor pathways within surface-confined application environments.
Experimental focus is generally directed toward receptor-associated signaling behavior, solvent-system compatibility, localized dispersion architecture, and controlled topical delivery modeling.
Research applications emphasize surface-confined topical carrier systems designed to support localized formulation behavior while minimizing broader systemic exposure variables within non-clinical study models.
This formulation is presented as a research-grade topical solution intended exclusively for scientific, analytical, and laboratory-based investigation under appropriately controlled handling conditions.
